Clinical trials: Type 2 Diabetic
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
- Trial name
- NCT00621140
- Testing
- linagliptin
- Where
- 69 sites in Croatia, India and 9 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
- Trial name
- NCT00282971
- Testing
- Inhaled Insulin (Exubera), Standard of Care
- Where
- 64 sites in Canada, France and 5 more
- Volunteers
- 354 people
- Sponsor
- Pfizer
Hypertension
A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)
This study will evaluate whether losartan protects the kidney in hypertensive Type II diabetic participants with microalbuminuria.
- Trial name
- NCT01390415
- Volunteers
- 136 people
- Sponsor
- Organon and Co
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per…
- Trial name
- NCT00976937
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sitagliptin
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 319 people
- Sponsor
- Sanofi
Type 2 Diabetes
Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone
The purpose of this study is to assess the safety and effectiveness of KRP-104 on glycemic control in patients with type 2 diabetes inadequately controlled on metformin alone.
- Trial name
- Synergy104 (NCT00995345)
- Testing
- KRP-104
- Where
- 45 sites in United States, Argentina and 5 more
- Volunteers
- 403 people
- Sponsor
- ActivX Biosciences, Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment as add-on therapy to metformin in…
- Trial name
- NCT01215097
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 306 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Diabetes Mellitus, Type 2
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- NCT01301456
- Testing
- PF-04856883
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.
- Trial name
- NCT01119846
- Testing
- GSK1292263, Sitagliptin
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetic Foot
Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care
This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard…
- Conditions
- Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT03626623
- Testing
- Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Integra LifeSciences Corporation
Diabetic Nephropathy
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
- Trial name
- NCT01712061
- Testing
- PF-04634817
- Where
- 142 sites in United States, Argentina and 12 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Hypertension, Type 2 Diabetes Mellitus
Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
This study will evaluate the effects of nebivolol on glycemic control compared with metoprolol and HCTZ in patients with hypertension and type 2 diabetes mellitus
- Trial name
- NCT00744237
- Testing
- Nebivolol, Metoprolol ER, HCTZ
- Where
- 65 sites in United States, Puerto Rico
- Volunteers
- 231 people
- Sponsor
- Forest Laboratories
Diabetes Mellitus, Type 2
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is inappropriate (intolerability, contraindication).
- Trial name
- NCT00740051
- Testing
- Linagliptin, Glimepiride
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 227 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
The objective of this study is to investigate the effect of BI 1356 on 24-h glucose control and various pharmacodynamic parameters in type 2 diabetic patients with inadequate glycaemic control.
- Trial name
- NCT00716092
- Testing
- Sitagliptin, Linagliptin
- Where
- 3 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled…
- Trial name
- NCT00295633
- Testing
- Saxagliptin, pioglitazone, rosiglitazone
- Where
- 133 sites in United States, Argentina and 6 more
- Volunteers
- 565 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Hypoglycemia
Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
The purpose of this study was to compare the effect of a fixed dose combination of vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in glycemic variability in patients with type 2 diabetes who…
- Trial name
- GLOBE (NCT02007278)
- Testing
- vildagliptin and metformin (combination), glimepiride, Metformin
- Where
- 8 sites in Colombia
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
The purpose of this study was to evaluate the efficacy and safety of 24-week treatment with metformin hydrochloride 500 mg once daily added on to alogliptin (SYR-322) 25 mg in type 2 diabetic patients with inadequate glycemic…
- Trial name
- NCT02068443
- Testing
- Alogliptin, Metformin hydrochloride
- Where
- 27 sites in Japan
- Volunteers
- 374 people
- Sponsor
- Takeda
Type 2 Diabetes
A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
This study is a Phase 2, randomized, double-blind, placebo-controlled, single-center study in adult patients with type 2 diabetes. It will evaluate the safety and tolerability of oral GLY-200.
- Trial name
- NCT05478525
- Testing
- GLY-200
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Glyscend, Inc.